This $633,376 Project Grant was awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of Alabama at Birmingham (UAB) on September 1, 2023. The grant supports epigenome editing research to reactivate the FOXP3 gene in breast cancer tumors, with the goal of developing new treatments. The research project is scheduled for completion by August 31, 2026. UAB is a public research university known for its interdisciplinary approach and has previously conducted biomedical and public health research funded by federal agencies such as NIH, CDC, and DoD.
Generated 4/9/24, 10:12 AM